Teva SPACE Pediatric Phase 3 Study Met Its Primary End Point For Efficacy With A Significantly Greater Reduction In Monthly Migraine Days Compared To Placebo; Efficacy Is Consistent With AJOVY Pivotal Phase 3 And Real-World Evidence Studies In Adults With No New Emergent Safety Signals Observed
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical Industries Ltd. announced positive topline results from its Phase 3 SPACE study evaluating AJOVY (fremanezumab) for preventing episodic migraine in children and adolescents. The study met its primary endpoint, showing significant efficacy over placebo with no new safety signals. Full data will be presented later in 2024.
July 18, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Teva's Phase 3 SPACE study for AJOVY in children met its primary endpoint, showing significant efficacy and no new safety signals. This positive result could boost investor confidence and potentially drive the stock price up.
The successful Phase 3 study for AJOVY in a new demographic (children and adolescents) demonstrates the drug's efficacy and safety, which is likely to positively impact investor sentiment and drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100